Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa

References

• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• Ott JJ, Horn J, Krause G, et al. Time trends of chronic HBV infection over prior decades - a global analysis. J Hepatol. 2017;66(1):48–54.
   PubMed Web of Science ®Google Scholar
• Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.
   PubMedGoogle Scholar
• Ho SY, Liu PH, Hsu CY, et al. Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. Sci Rep. 2020;10(1):3925.
   PubMed Web of Science ®Google Scholar
• Chien RN, Kao JH, Peng CY, et al. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118(1 Pt 1):7–38.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Yeh ML, Huang JF, Dai CY, et al. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opin Drug Metab Toxicol. 2019;15(10):779–785.
   PubMed Web of Science ®Google Scholar
• Seto WK, Hui AJ, Wong VW, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut. 2015;64(4):667–672.
   PubMed Web of Science ®Google Scholar
• Chen CH, Hung CH, Hu TH, et al. association between level of hepatitis b surface antigen and relapse after entecavir therapy for chronic Hepatitis B virus infection. Clin Gastroenterol Hepatol. 2015;13(11):1984–1992.
   PubMed Web of Science ®Google Scholar
• Seto WK, Liu KS, Mak LY, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut. 2020;gutjnl-2020-321116. DOI:https://doi.org/10.1136/gutjnl-2020-321116.
   Google Scholar
• Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137(6):2002–2009.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54(5):1591–1599.
   PubMed Web of Science ®Google Scholar
• Wang YC, Yang SS, Su CW, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep. 2016;6:29605.
   PubMed Web of Science ®Google Scholar
• Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56(5):699–705.
   PubMed Web of Science ®Google Scholar
• Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195.
   PubMed Web of Science ®Google Scholar
• Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196–206.
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–1104.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology. 2012;142(3):513–520.
   PubMed Web of Science ®Google Scholar
• Wei L, Wedemeyer H, Liaw YF, et al. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS One. 2018;13(7):e0199198.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013;57(3):890–896.
   PubMed Web of Science ®Google Scholar
• Boglione L, Cusato J, Allegra S, et al. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res. 2014;102:35–43.
   PubMed Web of Science ®Google Scholar
• Holmes JA, Nguyen T, Ratnam D, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. J Gastroenterol Hepatol. 2013;28(5):861–866.
   PubMed Web of Science ®Google Scholar
• Galmozzi E, Vigano M, Lampertico P. Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther. 2014;39(6):569–578.
   PubMed Web of Science ®Google Scholar
• Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther. 2011;16(5):629–637.
   PubMed Web of Science ®Google Scholar
• Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008;47(2):428–434.
   PubMed Web of Science ®Google Scholar
• Kuno A, Ikehara Y, Tanaka Y, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.
   PubMed Web of Science ®Google Scholar
• Yeh ML, Huang CF, Huang CI, et al. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS One. 2019;14(8):e0220663.
   PubMed Web of Science ®Google Scholar
• Huang CI, Huang CF, Yeh ML, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. Kaohsiung J Med Sci. 2017;33(8):394–399.
   PubMed Web of Science ®Google Scholar
• Jun T, Hsu YC, Ogawa S, et al. Mac-2 binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection. Hepatol Commun. 2019;3(4):493–503.
   PubMed Web of Science ®Google Scholar
• Zhu MY, Chen PZ, Li J, et al. Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-alpha treatment in HBeAg-positive chronic hepatitis B patients. J Med Virol. 2018;90(4):721–729.
   PubMed Web of Science ®Google Scholar
• Tamai H, Ida Y, Shingaki N, et al. Add-on pegylated interferon alpha-2a therapy in chronic Hepatitis B Japanese Patients Treated with Entecavir. Hepat Res Treat. 2017;2093847:2017.
   Google Scholar
• Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int. 2005;25(6):1097–1107.
   PubMed Web of Science ®Google Scholar
• Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol. 2011;26(Suppl 1):123–130.
   PubMed Web of Science ®Google Scholar
• Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther. 2008;13(2):211–220.
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–129.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136(7):2169–2179.
   PubMed Web of Science ®Google Scholar
• Mommeja-Marin H, Mondou E, Blum MR, et al. HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37(6):1309–1319.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2012;56(1):67–75.
   PubMed Web of Science ®Google Scholar
• Chuaypen N, Payungporn S, Poovorawan K, et al. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Virus Genes. 2019;55(5):610–618.
   PubMed Web of Science ®Google Scholar
• Yang HC, Chen CL, Shen YC, et al. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology. 2013;57(3):934–943.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51(6):1933–1944.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52(4):1251–1257.
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52(2):454–461.
   PubMed Web of Science ®Google Scholar
• Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. 2013;7(2):429–436.
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56(5):1006–1011.
   PubMed Web of Science ®Google Scholar
• Chuaypen N, Posuwan N, Payungporn S, et al., Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int. 2016;36(6): 827–836.
   PubMed Web of Science ®Google Scholar
• Beudeker BJ, Groothuismink ZM, de Man RA, et al. Hepatitis B core-related antigen levels predict pegylated interferon-alpha therapy response in HBeAg-positive chronic hepatitis B. Antivir Ther. 2020. DOI:https://doi.org/10.3851/IMP3367.
   Google Scholar
• van Campenhout MJH, Rijckborst V, Brouwer WP, et al. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. J Viral Hepat. 2019;26(10):1156–1163.
   PubMed Web of Science ®Google Scholar
• Chuaypen N, Posuwan N, Chittmittraprap S, et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. Clin Microbiol Infect. 2018;24(3):e307–306. e313. 306.
   Web of Science ®Google Scholar
• van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat. 2020;27(6):610–619.
   PubMed Web of Science ®Google Scholar
• Jia W, Zhu MQ, Qi X, et al. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J. 2019;16(1):61.
   PubMedGoogle Scholar
• van Bommel F, van Bommel A, Krauel A, et al., Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBeAg-positive chronic hepatitis b. J Infect Dis. 2018;218(7): 1066–1074.
   PubMed Web of Science ®Google Scholar
• Limothai U, Chuaypen N, Poovorawan K, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat. 2019;26(12):1481–1488.
   PubMed Web of Science ®Google Scholar
• Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to pegylated interferon alfa in hbeag negative chronic hepatitis b. Clin Infect Dis. 2020. DOI:https://doi.org/10.1093/cid/ciaa013
   Google Scholar
• Chan HLY, Messinger D, Papatheodoridis GV, et al., A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018;48(5): 547–555.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Messinger D, Oladipupo H, et al. An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings. Antivir Ther. 2018;23(8):655–663.
   PubMed Web of Science ®Google Scholar
• Yeh ML, Peng CY, Dai CY, et al. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS One. 2015;10(4):e0122259.
   PubMed Web of Science ®Google Scholar
• Hsu CW, Su WW, Lee CM, et al. Phase IV randomized clinical study: peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018;117(7):588–597.
   PubMed Web of Science ®Google Scholar
• Xie Q, Zhou H, Bai X, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B “e” antigen-positive chronic hepatitis B. Clin Infect Dis. 2014;59(12):1714–1723.
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–684.
   PubMed Web of Science ®Google Scholar
• Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther. 2009;14(8):1165–1174.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Wursthorn K, Wedemeyer H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol. 2015;62(1):41–47.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis b surface antigen in patients with chronic hepatitis b. Gastroenterology. 2016;150(1):134–144.
   PubMed Web of Science ®Google Scholar
• Li GJ, Yu YQ, Chen SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother. 2015;59(7):4121–4128.
   PubMed Web of Science ®Google Scholar
• Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis b: a multicenter randomized trial (ARES study. Hepatology. 2015;61(5):1512–1522.
   PubMed Web of Science ®Google Scholar
• Chi H, Hansen BE, Guo S, et al. Pegylated Interferon Alfa-2b add-on treatment in hepatitis b virus envelope antigen-positive chronic hepatitis b patients treated with nucleos(t)ide analogue: a randomized, controlled trial (PEGON. J Infect Dis. 2017;215(7):1085–1093.
   PubMed Web of Science ®Google Scholar
• van Campenhout MJH, Brouwer WP, Xie Q, et al. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat. 2019;26(1):109–117.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Rabiega P, Ganne-Carrie N, et al., Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017;2(3): 177–188.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Brunetto MR, Craxi A, et al. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D. J Viral Hepat. 2019;26(1):118–125.
   PubMed Web of Science ®Google Scholar
• Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial. J Hepatol. 2014;61(4):777–784.
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Nishiguchi S, Enomoto H, et al. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. J Gastroenterol. 2018;53(2):247–257.
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Nishiguchi S, Enomoto H, et al. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. J Gastroenterol. 2020;55(10):977–989.
   PubMed Web of Science ®Google Scholar